TrialThe Lancet. Oncology2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Ian E Krop et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
160 papers cite itlatest 60 shown
this paperpooled ittrialcites it